tiprankstipranks
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
US Market
KPRX
Kiora Pharmaceuticals
RESEARCH TOOLSreports

Kiora Pharmaceuticals (KPRX) Stock News & Sentiment

483 Followers
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
Premium
Ratings
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
6d ago
KPRX
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
Premium
Company Announcements
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
7d ago
8K
KPRX
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
Premium
Company Announcements
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
11d ago
8K
KPRX
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
Premium
Ratings
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
2M ago
KPRX
Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
5M ago
KPRX
Kiora Pharmaceuticals Reports Improved Financial Performance
Premium
Company Announcements
Kiora Pharmaceuticals Reports Improved Financial Performance
5M ago
KPRX
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
Premium
Company Announcements
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
6M ago
KPRX
More KPRX News >

KPRX News on the Web

Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
TipRanks News
Bullish
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
TipRanks News
Neutral
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX), Zentalis Pharmaceuticals (ZNTL) and Autolus Therapeutics (AUTL)
TipRanks News
Neutral
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
TipRanks News
Bullish
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright
The Fly
Neutral
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Zacks
Bullish
Kiora Pharmaceuticals Reports Q1 2025 Financial Results
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
KPRX
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KPRX’s Media Buzz Sentiment?
1 articles about KPRX were published this week. In an average week, 1 articles are published.
    What is KPRX’s weekly average amount of articles?
    In an average week, 1 articles about KPRX are published.
      What is KPRX’s News Sentiment?
      100% of articles about KPRX were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week